Gabrielle Masson

China-based Minghui Pharmaceutical has linked its thyroid eye disease treatment to a reduction in eye bulging in a small phase 1b/2 clinical trial.

On the heels of a phase 3 win that failed to impress investors, Ironwood Pharmaceuticals is back with more data in efforts to prove that its long-acting GLP-2 analog can do more than beat placebo.

Early data suggest Roche's antibody may safely and quickly remove amyloid plaque for patients with Alzheimer's disease, though the mid-stage study has been tied to one death.

Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any of the primary or secondary endpoints in a midstage study.

Beware: ghosts of biotech's past. Welcome to Fierce Biotech's graveyard, a yearly ritual in which we remember the companies that shuttered operations in 2024.

Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.

Paragon Therapeutics' spinout Jade Biosciences has entered a reverse merger with Aerovate Therapeutics that will allow Jade to start trading on the Nasdaq.

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships.

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline.

Swiss biotech Relief Therapeutics is slated to enter a reverse merger with private U.S. biotech Renexxion and forge ahead with the latter's gastrointestinal (GI) pipeline.